



HUTCHISON CHINA MEDITECH LTD

**Hutchison China MediTech Limited (“Chi-Med”)
(AIM: HCM)**

Block Admission Return

London, Thursday, 27 December 2007: Chi-Med announces the following block admission return:

Name of the company:	Hutchison China MediTech Limited
Name of the scheme:	Hutchison China MediTech Limited Share Option Scheme
Period of return:	From 26 June 2007 to 26 December 2007
Number and class of securities not issued under the scheme at the beginning of the period:	2,560,606 ordinary shares of US\$1 each
Number of securities issued under the scheme during the period:	17,053 ordinary shares of US\$1 each
Balance under the scheme of securities not yet issued at the end of the period:	2,543,553 ordinary shares of US\$1 each
Number and class of securities originally admitted and the date of admission:	2,560,606 ordinary shares of US\$1 each admitted on 26 June 2007

The total number of securities in issue at the end of the period was 51,229,174 ordinary shares of US\$1 each.

- Ends -

Enquiries

Chi-Med

Telephone: +852 2121 8200

Christian Hogg, CEO

Citigate Dewe Rogerson

Telephone: +44 (0) 20 7638 9571

Anthony Carlisle
Yvonne Alexander

Mobile: +44 (0) 7973 611 888
Mobile: +44 (0) 7866 610 682

About Chi-Med

Chi-Med is the holding company of a pharmaceutical and healthcare group based primarily in China and was admitted to trading on the Alternative Investment Market of the London Stock Exchange in May 2006. Chi-Med focuses on research, development, manufacture and sale of pharmaceuticals, health supplements and other consumer health and personal care products derived from Traditional Chinese Medicine and botanical ingredients.

Chi-Med is majority owned by Hutchison Whampoa Limited, an international corporation listed on the Main Board of The Stock Exchange of Hong Kong Limited.